Clinical trial
Combination Chemotherapy in Treating Women With Resected Breast Cancer
NCT00033683 · Institute of Cancer Research, United Kingdom, Other · Unknown status
Key facts
| NCT number | NCT00033683 |
|---|---|
| Title | Combination Chemotherapy in Treating Women With Resected Breast Cancer |
| Official title | A Randomised Trial Of Standard Anthracycline-Based Chemotherapy With Fluorouracil, Epirubicin And Cyclophosphamide (FEC) Or Epirubicin And CMF (Epi-CMF) Versus FEC Followed By Sequential Docetaxel As Adjuvant Treatment For Women With Early Breast Cancer |
| Lead sponsor | Institute of Cancer Research, United Kingdom, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | CMF regimen, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, methotrexate, tamoxifen citrate, adjuvant therapy, radiation therapy |
| Start date | Feb 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | Belgium, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: